Tirzepatide Mounjaro Gip/GLP-1 Receptor Agonist Obesity TreatmentPeptidepowder Weight Loss Therapy CAS 2023788-19-2

 Tirzepatide Mounjaro Gip/GLP-1 Receptor Agonist Obesity TreatmentPeptidepowder Weight Loss Therapy CAS 2023788-19-2

Porduct Description:

Product Information:
Products Name:Tirzepatide
CAS No.: 2023788-19-2
Purity: 99.0%min.(HPLC)
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.45g/mol
Sequence: Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2
Appearance: White Lyophilized powder
Storage:After reconstitution store at 2°C - 8°C

Description:
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual and agonist that is being developed for the treatment of type 2 diabetes.
GLP-1 agonists were approved by the FDA for weight loss in late 2014. It's a newer class of drugs better known for its ability to improve blood sugar control. These medications were actually designed to treat type II diabetes, but some have also been FDA approved to treat weight loss. The GLP-1 agonists we work with are called Semaglutide & Tirzepatide. Semaglutide is also known Ozempic or Wegovy. Tirzepatide is known as Mounjaro,which is dosed at 5-15mg per week,but we only can supply Tirzepatide powder.

Product Benefits:

• Helps slow food leaving your stomach
• Helps prevent your liver from making too much sugar
• Helps the pancreas produce more insul when your blood sugar levels are high
• Can help control blood glucose
• Can reduce hyperglycemia, especially after meals
• Can reduce fasting insul and fasting glucose
• Can reduce hemoglobin A1c
• Can decrease appetite and caloric intake, while inhibiting weight gain
• Has been shown to lower triglyceride levels and oxidative stress from high LDL
• Has been shown to help induce weight loss in obese patients with higher dosing
• Helps decrease leptin and increase leptin sensitivity
• Can increase the conversion of white fat to brown fat
•